Qihan Biotech
Hangzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
CRISPR-focused biotech developing off-the-shelf cell and in vivo gene therapies.
OncologyAutoimmuneGenetic Disorders
Technology Platform
A proprietary CRISPR-based gene-editing platform for developing allogeneic, off-the-shelf cell therapies and in vivo gene therapies, with a focus on immune evasion engineering.
Opportunities
Potential to define a new class of accessible, 'off-the-shelf' cellular medicines with broad applicability.
Risk Factors
Faces substantial technical and safety challenges associated with complex gene editing and allogeneic cell persistence.
Competitive Landscape
A high-science contender in the advanced allogeneic cell therapy space, competing with well-funded global biotechs.